wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q38079578-2161D454-AD02-45B7-B6B6-C366F3EF8350
Q38079578-2161D454-AD02-45B7-B6B6-C366F3EF8350
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38079578-2161D454-AD02-45B7-B6B6-C366F3EF8350
Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib.
P2860
Q38079578-2161D454-AD02-45B7-B6B6-C366F3EF8350
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38079578-2161D454-AD02-45B7-B6B6-C366F3EF8350
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
e47e6cacd67996ebc0300c386e3dbcc286791b0d
P2860
A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies.